{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:24:27Z","timestamp":1793982267147,"version":"4.8.0"},"reference-count":107,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.blre.2026.101384","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:06:51Z","timestamp":1772842011000},"page":"101384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Autoimmune hemolytic anemia: New frontiers in diagnosis and therapy"],"prefix":"10.1016","volume":"76","author":[{"given":"Wilma","family":"Barcellini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Fattizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.blre.2026.101384_bb0005","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMra2033982","article-title":"Autoimmune hemolytic anemias","volume":"385","author":"Berentsen","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2026.101384_bb0010","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41572-024-00566-2","article-title":"Autoimmune haemolytic anaemias","volume":"10","author":"Michel","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.blre.2026.101384_bb0015","series-title":"Autoimmune Hemolytic Anemias. A Practical Guide","author":"Barcellini","year":"2025"},{"issue":"4","key":"10.1016\/j.blre.2026.101384_bb0020","doi-asserted-by":"crossref","first-page":"E88","DOI":"10.1002\/ajh.25020","article-title":"Prognostic impact of bone marrow fibrosis and dyserythropoiesis in autoimmune hemolytic anemia","volume":"93","author":"Fattizzo","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2026.101384_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100648","article-title":"Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the first international consensus meeting","volume":"41","author":"J\u00e4ger","year":"2020","journal-title":"Blood Rev"},{"issue":"7","key":"10.1016\/j.blre.2026.101384_bb0030","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/1744666X.2022.2089115","article-title":"Autoimmune hemolytic anemia: causes and consequences","volume":"18","author":"Fattizzo","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"issue":"7","key":"10.1016\/j.blre.2026.101384_bb0035","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/17474086.2023.2216930","article-title":"Strategies to overcome the diagnostic challenges of autoimmune hemolytic anemias","volume":"16","author":"Barcellini","year":"2023","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"10.1016\/j.blre.2026.101384_bb0040","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1182\/hematology.2025000718","article-title":"Diagnosis and management of cold agglutinin disease","volume":"2025","author":"Berentsen","year":"2025","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"10.1016\/j.blre.2026.101384_bb0045","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1182\/hematology.2025000719","article-title":"Management of autoimmune hemolytic anemia","volume":"2025","author":"Barcellini","year":"2025","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"8","key":"10.1016\/j.blre.2026.101384_bb0050","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/MPH.0000000000002953","article-title":"Paroxysmal cold hemoglobinuria: mild to catastrophic-spectrum of a rare hemolytic anemia of childhood","volume":"46","author":"Agarwala","year":"2024","journal-title":"J Pediatr Hematol Oncol"},{"issue":"8","key":"10.1016\/j.blre.2026.101384_bb0055","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/ajh.27721","article-title":"Mixed autoimmune hemolytic Anemia: a systematic review of epidemiology, clinical characteristics, therapies, and outcomes","volume":"100","author":"Jacobs","year":"2025","journal-title":"Am J Hematol"},{"issue":"Suppl. 2","key":"10.1016\/j.blre.2026.101384_bb0060","first-page":"S47","article-title":"Pathogenesis and mechanisms of antibody-mediated hemolysis","volume":"55","author":"Flegel","year":"2015","journal-title":"Transfusion"},{"issue":"1","key":"10.1016\/j.blre.2026.101384_bb0065","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41392-025-02348-y","article-title":"Bone marrow microenvironment in autoimmune hemolytic anemia: from trephine biopsy to single cell RNA sequencing","volume":"10","author":"Fattizzo","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"10.1016\/j.blre.2026.101384_bb0070","doi-asserted-by":"crossref","first-page":"E291","DOI":"10.1002\/ajh.26213","article-title":"Epidemiology of autoimmune hemolytic anemia: a nationwide population-based study in France","volume":"96","author":"Maquet","year":"2021","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.blre.2026.101384_bb0075","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2147\/CLEP.S250250","article-title":"Increasing incidence and prevalence of acquired hemolytic anemias in Denmark, 1980-2016","author":"Hansen","year":"2020","journal-title":"Clin Epidemiol"},{"issue":"4","key":"10.1016\/j.blre.2026.101384_bb0080","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1182\/blood.2020005674","article-title":"Cold agglutinin disease revisited: a multinational, observational study of 232 patients","volume":"136","author":"Berentsen","year":"2020","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2026.101384_bb0085","doi-asserted-by":"crossref","first-page":"E371","DOI":"10.1002\/ajh.26665","article-title":"Characteristics and outcome of adults with severe autoimmune hemolytic anemia admitted to the intensive care unit: results from a large French observational study","volume":"97","author":"Pouchelon","year":"2022","journal-title":"Am J Hematol"},{"issue":"19","key":"10.1016\/j.blre.2026.101384_bb0090","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1182\/blood-2014-06-583021","article-title":"Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients","volume":"124","author":"Barcellini","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2026.101384_bb0095","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/ejh.13764","article-title":"Survival in autoimmune hemolytic anemia remains poor, results from a nationwide cohort with 37 years of follow-up","volume":"109","author":"Hansen","year":"2022","journal-title":"Eur J Haematol"},{"issue":"8","key":"10.1016\/j.blre.2026.101384_bb0100","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1111\/jth.15757","article-title":"Intravascular hemolysis and multitreatment predict thrombosis in patients with autoimmune hemolytic anemia","volume":"20","author":"Fattizzo","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"24","key":"10.1016\/j.blre.2026.101384_bb0105","doi-asserted-by":"crossref","first-page":"5468","DOI":"10.1182\/bloodadvances.2021005610","article-title":"Evans syndrome in adults: an observational multicenter study","volume":"5","author":"Fattizzo","year":"2021","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.blre.2026.101384_bb0110","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s11239-025-03129-8","article-title":"Prediction of thrombotic events in patients with autoimmune hemolytic anemia: a multicenter retrospective observational study","volume":"58","author":"Esteves","year":"2025","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"10.1016\/j.blre.2026.101384_bb0115","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/bjh.19242","article-title":"Primary autoimmune haemolytic anaemia is associated with increased risk of ischaemic stroke: A binational cohort study from Denmark and France","volume":"204","author":"Hansen","year":"2024","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2026.101384_bb0120","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/rth2.12333","article-title":"Increased risk of thrombotic events in cold agglutinin disease: A 10-year retrospective analysis","volume":"4","author":"Broome","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"10.1016\/j.blre.2026.101384_bb0125","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1365-3148.2003.00415.x","article-title":"A preliminary comparison of flow cytometry and tube agglutination assays in detecting red blood cell-associated C3d","volume":"13","author":"Stroncek","year":"2003","journal-title":"Transfus Med"},{"issue":"10","key":"10.1016\/j.blre.2026.101384_bb0130","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1046\/j.1537-2995.2001.41101258.x","article-title":"Comparison of DATs using traditional tube agglutination to gel column and affinity column procedures","volume":"41","author":"Dittmar","year":"2001","journal-title":"Transfusion"},{"issue":"5","key":"10.1016\/j.blre.2026.101384_bb0135","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/jcla.20033","article-title":"Comparison of conventional tube test technique and gel microcolumn assay for direct antiglobulin test: a large study","volume":"18","author":"Novaretti","year":"2004","journal-title":"J Clin Lab Anal"},{"issue":"5","key":"10.1016\/j.blre.2026.101384_bb0140","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s12185-010-0578-9","article-title":"Comparison of traditional methods and mitogen-stimulated direct antiglobulin test for detection of anti-red blood cell autoimmunity","volume":"91","author":"Barcellini","year":"2010","journal-title":"Int J Hematol"},{"issue":"4","key":"10.1016\/j.blre.2026.101384_bb0145","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2257.2006.00798.x","article-title":"Quantitation of red cell-bound IgG by an enzyme-linked antiglobulin test in the patients with warm-type autoimmune haemolytic anaemia","volume":"28","author":"Fabija\u0144ska-Mitek","year":"2006","journal-title":"Clin Lab Haematol"},{"issue":"2","key":"10.1016\/j.blre.2026.101384_bb0150","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ajh.21336","article-title":"Cut-off value of red-blood-cell-bound IgG for the diagnosis of coombs-negative autoimmune hemolytic anemia","volume":"84","author":"Kamesaki","year":"2009","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.blre.2026.101384_bb0155","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/j.1537-2995.2009.02533.x","article-title":"A dual antiglobulin test for the detection of weak or nonagglutinating immunoglobulin M warm autoantibodies","volume":"50","author":"Bartolm\u00e4s","year":"2010","journal-title":"Transfusion"},{"issue":"2","key":"10.1016\/j.blre.2026.101384_bb0160","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1537-2995.2008.01957.x","article-title":"Serologic findings in autoimmune hemolytic anemia associated with immunoglobulin M warm autoantibodies","volume":"49","author":"Arndt","year":"2009","journal-title":"Transfusion"},{"issue":"2","key":"10.1016\/j.blre.2026.101384_bb0165","first-page":"452","article-title":"In vitro quantification of anti-red blood cell antibody production in idiopathic autoimmune haemolytic anaemia: effect of mitogen and cytokine stimulation","volume":"111","author":"Barcellini","year":"2000","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.blre.2026.101384_bb0170","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1111\/trf.13257","article-title":"Detection of red blood cell antibodies in mitogen-stimulated cultures from patients with hereditary spherocytosis","volume":"55","author":"Zaninoni","year":"2015","journal-title":"Transfusion"},{"issue":"3","key":"10.1016\/j.blre.2026.101384_bb0175","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ajh.10210","article-title":"In vitro production of anti-RBC antibodies and cytokines in chronic lymphocytic leukemia","volume":"71","author":"Barcellini","year":"2002","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.blre.2026.101384_bb0180","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.leukres.2013.09.001","article-title":"Increased prevalence of autoimmune phenomena in myelofibrosis: relationship with clinical and morphological characteristics, and with immunoregulatory cytokine patterns","volume":"37","author":"Barcellini","year":"2013","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.blre.2026.101384_bb0185","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/10245330600915958","article-title":"Application of flow cytometry in detection of red-cell-bound IgG in Coombs-negative AIHA","volume":"11","author":"Chaudhary","year":"2006","journal-title":"Hematology"},{"issue":"3","key":"10.1016\/j.blre.2026.101384_bb0190","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1751-553X.2011.01397.x","article-title":"Role of gel test and flow cytometry in diagnosis of Coombs\u2019 negative autoimmune haemolytic anaemia","volume":"34","author":"Fayek","year":"2012","journal-title":"Int J Lab Hematol"},{"issue":"7","key":"10.1016\/j.blre.2026.101384_bb0195","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/j.1537-2995.2009.02130.x","article-title":"Clinical application of a flow cytometric direct antiglobulin test","volume":"49","author":"Lin","year":"2009","journal-title":"Transfusion"},{"issue":"3","key":"10.1016\/j.blre.2026.101384_bb0200","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/ijlh.12297","article-title":"Simultaneous detection of IgG, IgM, IgA complexes and C3d attached to erythrocytes by flow cytometry","volume":"37","author":"Alzate","year":"2015","journal-title":"Int J Lab Hematol"},{"issue":"3","key":"10.1016\/j.blre.2026.101384_bb0205","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/joim.13753","article-title":"Transfusions in autoimmune hemolytic anemias: frequency and clinical significance of alloimmunization","volume":"295","author":"Versino","year":"2024","journal-title":"J Intern Med"},{"issue":"1","key":"10.1016\/j.blre.2026.101384_bb0210","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3324\/haematol.10546","article-title":"Anti-erythroblast autoimmunity in early myelodysplastic syndromes","volume":"92","author":"Barcellini","year":"2007","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.blre.2026.101384_bb0215","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1111\/trf.13652","article-title":"Detection of erythroblast antibodies in mitogen-stimulated bone marrow cultures from patients with myelodysplastic syndromes","volume":"56","author":"Zaninoni","year":"2016","journal-title":"Transfusion"},{"key":"10.1016\/j.blre.2026.101384_bb0220","article-title":"Characterization of complement and immunoglobulin deposition in bone marrow trephine biopsies of patients with cytopenias","author":"Fidanza","year":"2025","journal-title":"Abstract EHA"},{"issue":"3","key":"10.1016\/j.blre.2026.101384_bb0225","doi-asserted-by":"crossref","first-page":"E26","DOI":"10.1002\/ajh.24618","article-title":"Clinical evolution of autoimmune cytopenias to idiopathic cytopenias\/dysplasias of uncertain significance (ICUS\/IDUS) and bone marrow failure syndromes","volume":"92","author":"Barcellini","year":"2017","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.blre.2026.101384_bb0230","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3324\/haematol.2020.250522","article-title":"Efficacy of recombinant erythropoietin in autoimmune hemolytic anemia: a multicenter international study","volume":"106","author":"Fattizzo","year":"2021","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.blre.2026.101384_bb0235","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1182\/bloodadvances.2023012297","article-title":"Add-on erythropoietin in autoimmune hemolytic anemia","volume":"8","author":"Moser","year":"2024","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.blre.2026.101384_bb0240","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1159\/000366244","article-title":"The effect of erythropoiesis-stimulating agents in patients with therapy-refractory autoimmune hemolytic anemia","volume":"41","author":"Salama","year":"2014","journal-title":"Transfus Med Hemother"},{"issue":"5","key":"10.1016\/j.blre.2026.101384_bb0245","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1182\/bloodadvances.2023011798","article-title":"Recombinant erythropoietin in autoimmune hemolytic anemia with inadequate bone marrow response: a prospective analysis","volume":"8","author":"Fattizzo","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101384_bb0250","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.autrev.2014.11.014","article-title":"Efficacy and safety of rituximab in auto-immune hemolytic anemia: a meta-analysis of 21 studies","volume":"14","author":"Reynaud","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.blre.2026.101384_bb0255","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ajh.24570","article-title":"A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study)","volume":"92","author":"Michel","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2026.101384_bb0260","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/bjh.12541","article-title":"A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia","volume":"163","author":"Birgens","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101384_bb0265","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1182\/blood-2010-06-288647","article-title":"High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease","volume":"116","author":"Berentsen","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101384_bb0270","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2017-04-778175","article-title":"Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial","volume":"130","author":"Berentsen","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2026.101384_bb0275","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1182\/bloodadvances.2024013067","article-title":"Risk of hospitalization with infection in adults with primary AIHA treated with rituximab: a French nationwide study","volume":"9","author":"Zadro","year":"2025","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.blre.2026.101384_bb0280","doi-asserted-by":"crossref","first-page":"E243","DOI":"10.1002\/ajh.25212","article-title":"Predictors of refractoriness to therapy and healthcare resource utilization in 378 patients with primary autoimmune hemolytic anemia from eight Italian reference centers","volume":"93","author":"Barcellini","year":"2018","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.blre.2026.101384_bb0285","doi-asserted-by":"crossref","first-page":"5863","DOI":"10.1007\/s00464-022-09116-x","article-title":"Clinical and surgical outcomes of splenectomy for autoimmune hemolytic anemia","volume":"36","author":"Maskal","year":"2022","journal-title":"Surg Endosc"},{"key":"10.1016\/j.blre.2026.101384_bb0290","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.amjsurg.2012.05.030","article-title":"Outcomes and complications after splenectomy for hematologic disorders","volume":"204","author":"Patel","year":"2012","journal-title":"Am J Surg"},{"key":"10.1016\/j.blre.2026.101384_bb0295","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/ajh.2830440404","article-title":"Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients","volume":"44","author":"Flores","year":"1993","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.blre.2026.101384_bb0300","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1002\/ajh.27361","article-title":"Intravenous immunoglobulin as a rescue therapy for severe adult autoimmune hemolytic anemia: results from a French multicenter observational study","volume":"99","author":"Michel","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2026.101384_bb0305","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/jca.22043","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American society for apheresis: the ninth special issue","volume":"38","author":"Connelly-Smith","year":"2023","journal-title":"J Clin Apher"},{"key":"10.1016\/j.blre.2026.101384_bb0310","doi-asserted-by":"crossref","first-page":"1228142","DOI":"10.3389\/fimmu.2023.1228142","article-title":"Severe autoimmune hemolytic anemia; epidemiology, clinical management, outcomes and knowledge gaps","volume":"14","author":"Mulder","year":"2023","journal-title":"Front Immunol"},{"issue":"20","key":"10.1016\/j.blre.2026.101384_bb0315","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1182\/blood.2021012039","article-title":"Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease\/cold agglutinin syndrome","volume":"138","author":"Jalink","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2026.101384_bb0320","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2025-4655","article-title":"Long-term efficacy and safety of rilzabrutinib, an oral bruton tyrosine kinase (BTK) inhibitor in patients with warm autoimmune hemolytic anemia (wAIHA) in the LUMINA phase 2b part B study: A 74-week follow-up","volume":"146","author":"Fattizzo","year":"2025","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2026.101384_bb0325","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood-2025-1123","article-title":"Phase 3 study to evaluate the efficacy and safety of rilzabrutinib in primary warm autoimmune hemolytic anemia (wAIHA): LUMINA 3","volume":"146","author":"Kuter","year":"2025","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2026.101384_bb0330","first-page":"355","article-title":"Efficacy and safety of zanubrutinib in treating refractory\/relapsed warm autoimmune hemolytic anemia","volume":"46","author":"Shen","year":"2025","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"12","key":"10.1016\/j.blre.2026.101384_bb0335","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/ajh.27493","article-title":"Parsaclisib for the treatment of primary autoimmune hemolytic anemia: results from a phase 2, open-label study","volume":"99","author":"Barcellini","year":"2024","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.blre.2026.101384_bb0340","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1182\/bloodadvances.2025017722","article-title":"Effect of obexelimab on the production of anti-RBC ab and cytokines from patients with warm autoimmune hemolytic anemia","volume":"10","author":"Fattizzo","year":"2026","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.blre.2026.101384_bb0345","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.3390\/biomedicines12071597","article-title":"Anti-B-cell-activating factor (BAFF) therapy: a novel addition to autoimmune disease management and potential for immunomodulatory therapy in warm autoimmune hemolytic Anemia","volume":"12","author":"Cheekati","year":"2024","journal-title":"Biomedicines"},{"issue":"Suppl","key":"10.1016\/j.blre.2026.101384_bb0350","article-title":"VAIHA: a randomized, double-blind, phase III trial to assess the efficacy and safety of ianalumab vs placebo in patients with warm autoimmune hemolytic anemia that failed \u22651 line of treatment","volume":"7","author":"Barcellini","year":"2023","journal-title":"Hemasphere"},{"issue":"Suppl","key":"10.1016\/j.blre.2026.101384_bb0355","article-title":"S276: Povetacicept (ALPN-303), a potent dual Baff\/April antagonist, for the treatment of autoimmune cytopenias and other antibody-related diseases","volume":"7","author":"Dillon","year":"2023","journal-title":"HemaSphere"},{"key":"10.1016\/j.blre.2026.101384_bb0360","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaut.2015.05.006","article-title":"Emergence of long-lived autoreactive plasma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximab","volume":"62","author":"Mah\u00e9vas","year":"2015","journal-title":"J Autoimmun"},{"issue":"5","key":"10.1016\/j.blre.2026.101384_bb0365","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1182\/blood-2018-03-835413","article-title":"Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study","volume":"132","author":"Rossi","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2026.101384_bb0370","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/ajh.27540","article-title":"Rituximab plus Bortezomib for relapsed and refractory warm autoimmune hemolytic Anemia: a prospective phase 2 trial","volume":"100","author":"Lin","year":"2025","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.blre.2026.101384_bb0375","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000028679","article-title":"Combination of low-dose rituximab, bortezomib and dexamethasone for the treatment of autoimmune hemolytic anemia","volume":"101","author":"Yao","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.blre.2026.101384_bb0380","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211046428","article-title":"Bortezomib in autoimmune hemolytic anemia and beyond","volume":"12","author":"Pasquale","year":"2021","journal-title":"Ther Adv Hematol"},{"issue":"11","key":"10.1016\/j.blre.2026.101384_bb0385","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1182\/bloodadvances.2024012585","article-title":"Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease","volume":"8","author":"Jalink","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101384_bb0390","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.649441","article-title":"The immunomodulatory effect and clinical efficacy of Daratumumab in a patient with cold agglutinin disease","volume":"12","author":"Zaninoni","year":"2021","journal-title":"Front Immunol"},{"issue":"19","key":"10.1016\/j.blre.2026.101384_bb0395","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1182\/bloodadvances.2018020883","article-title":"Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation","volume":"2","author":"Schuetz","year":"2018","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.blre.2026.101384_bb0400","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ajh.26508","article-title":"Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: phase 2, multicenter, open-label study","volume":"97","author":"Kuter","year":"2022","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.blre.2026.101384_bb0405","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ajh.27144","article-title":"Fostamatinib for warm antibody autoimmune hemolytic anemia: phase 3, randomized, double-blind, placebo-controlled, global study (FORWARD)","volume":"99","author":"Kuter","year":"2024","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.blre.2026.101384_bb0410","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1016\/S2352-3026(24)00344-2","article-title":"Sovleplenib in patients with primary or secondary warm autoimmune haemolytic anaemia: results from phase 2 of a randomised, double-blind, placebo-controlled, phase 2\/3 study","volume":"12","author":"Zhao","year":"2025","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2026.101384_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2025.101328","article-title":"Targeting the neonatal fc receptor (FcRn) in hematologic conditions with a focus on warm autoimmune hemolytic anemia","volume":"74","author":"Fattizzo","year":"2025","journal-title":"Blood Rev"},{"issue":"6","key":"10.1016\/j.blre.2026.101384_bb0420","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1111\/bjh.17872","article-title":"Novel therapies for immune thrombocytopenia","volume":"196","author":"Kuter","year":"2022","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2026.101384_bb0425","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3390\/antib14030065","article-title":"FcRn blockade as a targeted therapeutic strategy in antibody-mediated autoimmune diseases: a focus on warm autoimmune hemolytic anemia","volume":"14","author":"Sandhu","year":"2025","journal-title":"Antibodies (Basel)"},{"issue":"16","key":"10.1016\/j.blre.2026.101384_bb0430","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1182\/blood-2009-01-196329","article-title":"Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease","volume":"113","author":"R\u00f6th","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101384_bb0435","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1182\/bloodadvances.2018024190","article-title":"Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial","volume":"2","author":"R\u00f6th","year":"2018","journal-title":"Blood Adv"},{"issue":"26","key":"10.1016\/j.blre.2026.101384_bb0440","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1182\/blood-2014-02-556027","article-title":"TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins","volume":"123","author":"Shi","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2026.101384_bb0445","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2018-06-856930","article-title":"Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial","volume":"133","author":"J\u00e4ger","year":"2019","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.blre.2026.101384_bb0450","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJMoa2027760","article-title":"Sutimlimab in cold agglutinin disease","volume":"384","author":"R\u00f6th","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.blre.2026.101384_bb0455","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1007\/s00277-022-04948-y","article-title":"Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study","volume":"101","author":"R\u00f6th","year":"2022","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.blre.2026.101384_bb0460","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1182\/blood.2021014955","article-title":"Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial","volume":"140","author":"R\u00f6th","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2026.101384_bb0465","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.3324\/haematol.2021.279812","article-title":"Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results","volume":"107","author":"Roth","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2026.101384_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102733","article-title":"Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B","volume":"74","author":"R\u00f6th","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"8","key":"10.1016\/j.blre.2026.101384_bb0475","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/ajh.26965","article-title":"Sustained inhibition of complement C1s with sutimlimab over 2years in patients with cold agglutinin disease","volume":"98","author":"R\u00f6th","year":"2023","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.blre.2026.101384_bb0480","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/17474086.2023.2218611","article-title":"Complement-directed therapy for cold agglutinin disease: sutimlimab","volume":"16","author":"Broome","year":"2023","journal-title":"Expert Rev Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2026.101384_bb0485","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1182\/blood-2025-1100","article-title":"Real world use of sutimlimab in patients with cold agglutinin disease: an international study","volume":"146","author":"Fattizzo","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101384_bb0490","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1080\/19420862.2019.1633883","article-title":"Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life","volume":"11","author":"Mackness","year":"2019","journal-title":"MAbs"},{"key":"10.1016\/j.blre.2026.101384_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109629","article-title":"Anti-C1s humanized monoclonal antibody SAR445088: A classical pathway complement inhibitor specific for the active form of C1s","volume":"251","author":"Simmons","year":"2023","journal-title":"Clin Immunol"},{"issue":"8","key":"10.1016\/j.blre.2026.101384_bb0500","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood.2023022153","article-title":"Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study","volume":"143","author":"D\u2019Sa","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2026.101384_bb0505","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/ajh.70147","article-title":"Iptacopan for immune thrombocytopenia and cold agglutinin disease: a Global Phase 2 Basket Clinical Trial","volume":"101","author":"R\u00f6th","year":"2026","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.blre.2026.101384_bb0510","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood.2023022549","article-title":"Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemia","volume":"145","author":"Roman","year":"2025","journal-title":"Blood"},{"issue":"Suppl","key":"10.1016\/j.blre.2026.101384_bb0515","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1097\/01.HS9.0000849064.31599.55","article-title":"P1552: a phase 2, open-label study to assess safety, tolerability, and clinical effect of anx005 in patients with warm autoimmune hemolytic anemia and evidence of complement activation","volume":"6","author":"Jaeger","year":"2022","journal-title":"Hemasphere"},{"issue":"4","key":"10.1016\/j.blre.2026.101384_bb0520","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.jaci.2020.08.028","article-title":"ARGX-117, a therapeutic complement inhibiting antibody targeting C2","volume":"147","author":"Van de Walle","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2026.101384_bb0525","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1182\/blood-2024-202980","article-title":"CD19 CAR T-cell therapy in refractory autoimmune hemolytic anemia","volume":"144","author":"Li","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2026.101384_bb0530","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJMoa2509820","article-title":"CD19 CAR T-cell therapy for autoimmune hemolytic anemia","volume":"394","author":"Li","year":"2026","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.blre.2026.101384_bb0535","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1056\/NEJMc2502297","article-title":"BCMA-targeted T-cell engager for autoimmune hemolytic anemia after CD19 CAR T-cell therapy","volume":"392","author":"Zhang","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X26000238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X26000238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:11:29Z","timestamp":1788221489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X26000238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":107,"alternative-id":["S0268960X26000238"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2026.101384","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoimmune hemolytic anemia: New frontiers in diagnosis and therapy","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2026.101384","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101384"}}